{"id":1817,"date":"2021-03-20T15:10:00","date_gmt":"2021-03-20T14:10:00","guid":{"rendered":"https:\/\/hemerion.com\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/"},"modified":"2022-06-03T17:30:23","modified_gmt":"2022-06-03T15:30:23","slug":"resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics","status":"publish","type":"post","link":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/","title":{"rendered":"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour le traitement du glioblastome d\u00e9velopp\u00e9 par Hemerion"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>La revue Journal of Neuro-Oncology a publi\u00e9 samedi 20 mars 2021 les premiers r\u00e9sultats cliniques de la technologie d\u00e9velopp\u00e9e par Hemerion pour le traitement du glioblastome, l\u2019un des cancers du cerveau les plus r\u00e9pandus et les plus agressifs.<br>Ces r\u00e9sultats d\u00e9montrent la tr\u00e8s bonne tol\u00e9rance du traitement et sont tr\u00e8s encourageants au niveau de l\u2019efficacit\u00e9 : une validation qui ouvre la voie aux essais cliniques de phase II.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Avec plus de de 25 000 nouveaux diagnostics par an en Europe et aux Etats-Unis et une dur\u00e9e m\u00e9diane de survie de 15 mois, le <strong>glioblastome<\/strong> est un probl\u00e8me de sant\u00e9 publique majeur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les traitements actuels visent la destruction de la tumeur avec la combinaison de trois modalit\u00e9s : <strong>la chirurgie<\/strong> (r\u00e9section de la tumeur), <strong>la chimioth\u00e9rapie<\/strong> et <strong>la radioth\u00e9rapie<\/strong>. Ces traitements ralentissent la progression de la tumeur sans pouvoir l\u2019\u00e9radiquer compl\u00e8tement. De plus, ils endommagent des cellules saines et laissent en place des cellules tumorales qui provoquent des r\u00e9cidives et r\u00e9duisent l\u2019esp\u00e9rance de vie des patients. Le caract\u00e8re agressif du glioblastome am\u00e8ne quasiment syst\u00e9matiquement une rechute locale et r\u00e9duit l&rsquo;esp\u00e9rance de vie des patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La technologie propos\u00e9e par Hemerion pour le <a href=\"https:\/\/hemerion.com\/fr\/solutions-therapeutiques\/\">traitement du glioblastome<\/a> repose sur la combinaison sans pr\u00e9c\u00e9dent d&rsquo;un m\u00e9dicament photosensibilisant et d&rsquo;un dispositif photonique innovant : <strong>une lumi\u00e8re laser<\/strong> d\u00e9di\u00e9e et un \u00e9quipement d&rsquo;illumination <strong>adapt\u00e9 \u00e0 la chirurgie du cerveau<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Son objectif : d\u00e9truire les cellules canc\u00e9reuses r\u00e9siduelles, en compl\u00e9ment des traitements existants pour \u00e9viter les r\u00e9cidives, allonger la survie et am\u00e9liorer la qualit\u00e9 de vie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les r\u00e9sultats publi\u00e9s par Journal of Neuro-Oncology portent sur l\u2019essai clinique de phase I (\u00e9valuation de la faisabilit\u00e9 et de la toxicit\u00e9) intitul\u00e9 INDYGO (intraoperative photodynamic therapy for glioblastomas). L\u2019essai a \u00e9t\u00e9 men\u00e9 par une \u00e9quipe de recherche de l&rsquo;<a href=\"https:\/\/www.univ-lille.fr\/\">Universit\u00e9 de Lille<\/a> et de l\u2019<a href=\"https:\/\/www.inserm.fr\/\">Inserm<\/a> (unit\u00e9 de recherche OncoThAI Inserm U1189) et le service de neurochirurgie du Centre Hospitalier Universitaire de Lille, promoteur de l\u2019\u00e9tude clinique INDYGO.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Il portait sur 10 patients atteints d\u2019un glioblastome r\u00e9cemment diagnostiqu\u00e9, trait\u00e9s entre mai 2017 et juin 2018 au Centre Hospitalier Universitaire de Lille.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ce traitement, aujourd\u2019hui d\u00e9velopp\u00e9 par Hemerion, a \u00e9t\u00e9 appliqu\u00e9 au cours des op\u00e9rations chirurgicales visant \u00e0 retirer la tumeur. Les patients recevaient quelques heures avant l&rsquo;op\u00e9ration une dose de photosensibilisateur, une mol\u00e9cule pharmaceutique qui p\u00e9n\u00e8tre et s\u2019accumule dans les cellules canc\u00e9reuses, mais est \u00e9limin\u00e9e par les cellules saines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Au cours de l\u2019intervention chirurgicale, apr\u00e8s la r\u00e9section de la tumeur, le dispositif photonique diffuse une lumi\u00e8re laser sp\u00e9cifique, qui active le photosensibilisateur et provoque des r\u00e9actions qui aboutissent \u00e0 la <strong>destruction des cellules canc\u00e9reuses<\/strong>. La tumeur est \u00e9limin\u00e9e partout o\u00f9 la lumi\u00e8re p\u00e9n\u00e8tre.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les patients ont \u00e9t\u00e9 suivis tous les 3 mois suite \u00e0 l\u2019op\u00e9ration par les \u00e9quipes du CHU de Lille, afin de v\u00e9rifier la s\u00e9curit\u00e9 du traitement, sa tol\u00e9rance et r\u00e9aliser une premi\u00e8re \u00e9valuation de son efficacit\u00e9. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les r\u00e9sultats sont tr\u00e8s positifs sur la s\u00e9curit\u00e9 et la tol\u00e9rance du traitement : aucun effet secondaire li\u00e9 au traitement n\u2019a \u00e9t\u00e9 enregistr\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u2019autre part, cette \u00e9tude montre des premiers r\u00e9sultats d\u2019efficacit\u00e9 tr\u00e8s encourageants : on observe pour la moiti\u00e9 des patients trait\u00e9s une survie sans progression sup\u00e9rieure \u00e0 17 mois et d\u2019une survie globale sup\u00e9rieure \u00e0 23 mois.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces constats permettent \u00e0 Hemerion de lancer rapidement des essais cliniques plus pouss\u00e9s pour \u00e9valuer pr\u00e9cis\u00e9ment l\u2019efficacit\u00e9 de ce traitement innovant.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La revue Journal of Neuro-Oncology a publi\u00e9 samedi 20 mars 2021 les premiers r\u00e9sultats cliniques de la technologie d\u00e9velopp\u00e9e par Hemerion pour le traitement du glioblastome, l\u2019un des cancers du cerveau les plus r\u00e9pandus et les plus agressifs.Ces r\u00e9sultats d\u00e9montrent la tr\u00e8s bonne tol\u00e9rance du traitement et sont tr\u00e8s encourageants au niveau de l\u2019efficacit\u00e9 : &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour le traitement du glioblastome d\u00e9velopp\u00e9 par Hemerion\" class=\"read-more button\" href=\"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#more-1817\" aria-label=\"En savoir plus sur R\u00e9sultats cliniques pr\u00e9liminaires positifs pour le traitement du glioblastome d\u00e9velopp\u00e9 par Hemerion\">Lire plus<\/a><\/p>\n","protected":false},"author":207845439,"featured_media":1764,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_jet_sm_ready_style":"","_jet_sm_style":"","_jet_sm_controls_values":"","_jet_sm_fonts_collection":"","_jet_sm_fonts_links":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[6342],"tags":[],"class_list":["post-1817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>R\u00e9sultats cliniques pr\u00e9liminaires positifs pour la technologie Hemerion.<\/title>\n<meta name=\"description\" content=\"Le &quot;Journal of Neuro-Oncology&quot; a publi\u00e9 les premiers r\u00e9sultats cliniques de la technologie Hemerion dans le traitement du glioblastome.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour la technologie Hemerion.\" \/>\n<meta property=\"og:description\" content=\"Le &quot;Journal of Neuro-Oncology&quot; a publi\u00e9 les premiers r\u00e9sultats cliniques de la technologie Hemerion dans le traitement du glioblastome.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Hemerion\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-20T14:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-03T15:30:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hemerion.com\/wp-content\/uploads\/1620142558175.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dominique Maeker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HemerionTx\" \/>\n<meta name=\"twitter:site\" content=\"@HemerionTx\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dominique Maeker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/\"},\"author\":{\"name\":\"Dominique Maeker\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/person\\\/0d627e77d4bfc450cd055bf3010b65d5\"},\"headline\":\"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour le traitement du glioblastome d\u00e9velopp\u00e9 par Hemerion\",\"datePublished\":\"2021-03-20T14:10:00+00:00\",\"dateModified\":\"2022-06-03T15:30:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/\"},\"wordCount\":639,\"publisher\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/1620142558175.jpeg?fit=800%2C1000&ssl=1\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/\",\"name\":\"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour la technologie Hemerion.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/1620142558175.jpeg?fit=800%2C1000&ssl=1\",\"datePublished\":\"2021-03-20T14:10:00+00:00\",\"dateModified\":\"2022-06-03T15:30:23+00:00\",\"description\":\"Le \\\"Journal of Neuro-Oncology\\\" a publi\u00e9 les premiers r\u00e9sultats cliniques de la technologie Hemerion dans le traitement du glioblastome.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/1620142558175.jpeg?fit=800%2C1000&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/1620142558175.jpeg?fit=800%2C1000&ssl=1\",\"width\":800,\"height\":1000,\"caption\":\"Hemerion featured in the Journal of Neuro-Oncology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour le traitement du glioblastome d\u00e9velopp\u00e9 par Hemerion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\",\"name\":\"Hemerion\",\"description\":\"Advancing cancer therapies at the speed of light\",\"publisher\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\",\"name\":\"Hemerion\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-logo.png?fit=1581%2C460&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-logo.png?fit=1581%2C460&ssl=1\",\"width\":1581,\"height\":460,\"caption\":\"Hemerion\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/HemerionTx\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hemerion-therapeutics\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCWwcUj-aSdo32OYwN5vjf8Q\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/person\\\/0d627e77d4bfc450cd055bf3010b65d5\",\"name\":\"Dominique Maeker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7c6eba69bd9b57ed819d4a1bc57b9db9cb0b97bbcbeff06d7b640313bfbe3bf?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7c6eba69bd9b57ed819d4a1bc57b9db9cb0b97bbcbeff06d7b640313bfbe3bf?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7c6eba69bd9b57ed819d4a1bc57b9db9cb0b97bbcbeff06d7b640313bfbe3bf?s=96&d=identicon&r=g\",\"caption\":\"Dominique Maeker\"},\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/author\\\/dominiquemaeker0240\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour la technologie Hemerion.","description":"Le \"Journal of Neuro-Oncology\" a publi\u00e9 les premiers r\u00e9sultats cliniques de la technologie Hemerion dans le traitement du glioblastome.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/","og_locale":"fr_FR","og_type":"article","og_title":"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour la technologie Hemerion.","og_description":"Le \"Journal of Neuro-Oncology\" a publi\u00e9 les premiers r\u00e9sultats cliniques de la technologie Hemerion dans le traitement du glioblastome.","og_url":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/","og_site_name":"Hemerion","article_published_time":"2021-03-20T14:10:00+00:00","article_modified_time":"2022-06-03T15:30:23+00:00","og_image":[{"width":800,"height":1000,"url":"https:\/\/hemerion.com\/wp-content\/uploads\/1620142558175.jpeg","type":"image\/jpeg"}],"author":"Dominique Maeker","twitter_card":"summary_large_image","twitter_creator":"@HemerionTx","twitter_site":"@HemerionTx","twitter_misc":{"\u00c9crit par":"Dominique Maeker","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#article","isPartOf":{"@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/"},"author":{"name":"Dominique Maeker","@id":"https:\/\/hemerion.com\/fr\/#\/schema\/person\/0d627e77d4bfc450cd055bf3010b65d5"},"headline":"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour le traitement du glioblastome d\u00e9velopp\u00e9 par Hemerion","datePublished":"2021-03-20T14:10:00+00:00","dateModified":"2022-06-03T15:30:23+00:00","mainEntityOfPage":{"@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/"},"wordCount":639,"publisher":{"@id":"https:\/\/hemerion.com\/fr\/#organization"},"image":{"@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/1620142558175.jpeg?fit=800%2C1000&ssl=1","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/","url":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/","name":"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour la technologie Hemerion.","isPartOf":{"@id":"https:\/\/hemerion.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/1620142558175.jpeg?fit=800%2C1000&ssl=1","datePublished":"2021-03-20T14:10:00+00:00","dateModified":"2022-06-03T15:30:23+00:00","description":"Le \"Journal of Neuro-Oncology\" a publi\u00e9 les premiers r\u00e9sultats cliniques de la technologie Hemerion dans le traitement du glioblastome.","breadcrumb":{"@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#primaryimage","url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/1620142558175.jpeg?fit=800%2C1000&ssl=1","contentUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/1620142558175.jpeg?fit=800%2C1000&ssl=1","width":800,"height":1000,"caption":"Hemerion featured in the Journal of Neuro-Oncology"},{"@type":"BreadcrumbList","@id":"https:\/\/hemerion.com\/fr\/resultats-cliniques-preliminaires-positifs-pour-le-traitement-du-glioblastome-developpe-par-hemerion-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hemerion.com\/fr\/"},{"@type":"ListItem","position":2,"name":"R\u00e9sultats cliniques pr\u00e9liminaires positifs pour le traitement du glioblastome d\u00e9velopp\u00e9 par Hemerion"}]},{"@type":"WebSite","@id":"https:\/\/hemerion.com\/fr\/#website","url":"https:\/\/hemerion.com\/fr\/","name":"Hemerion","description":"Advancing cancer therapies at the speed of light","publisher":{"@id":"https:\/\/hemerion.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hemerion.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/hemerion.com\/fr\/#organization","name":"Hemerion","url":"https:\/\/hemerion.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/hemerion.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-logo.png?fit=1581%2C460&ssl=1","contentUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-logo.png?fit=1581%2C460&ssl=1","width":1581,"height":460,"caption":"Hemerion"},"image":{"@id":"https:\/\/hemerion.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/HemerionTx","https:\/\/www.linkedin.com\/company\/hemerion-therapeutics\/","https:\/\/www.youtube.com\/channel\/UCWwcUj-aSdo32OYwN5vjf8Q"]},{"@type":"Person","@id":"https:\/\/hemerion.com\/fr\/#\/schema\/person\/0d627e77d4bfc450cd055bf3010b65d5","name":"Dominique Maeker","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/e7c6eba69bd9b57ed819d4a1bc57b9db9cb0b97bbcbeff06d7b640313bfbe3bf?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e7c6eba69bd9b57ed819d4a1bc57b9db9cb0b97bbcbeff06d7b640313bfbe3bf?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e7c6eba69bd9b57ed819d4a1bc57b9db9cb0b97bbcbeff06d7b640313bfbe3bf?s=96&d=identicon&r=g","caption":"Dominique Maeker"},"url":"https:\/\/hemerion.com\/fr\/author\/dominiquemaeker0240\/"}]}},"jetpack_shortlink":"https:\/\/wp.me\/pd9WhZ-tj","jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/1620142558175.jpeg?fit=800%2C1000&ssl=1","_links":{"self":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts\/1817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/users\/207845439"}],"replies":[{"embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/comments?post=1817"}],"version-history":[{"count":24,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts\/1817\/revisions"}],"predecessor-version":[{"id":3499,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts\/1817\/revisions\/3499"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/media\/1764"}],"wp:attachment":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/media?parent=1817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/categories?post=1817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/tags?post=1817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}